BARCLAYS PLC - PROTAGONIST THERAPEUTICS INC ownership

PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 65 filers reported holding PROTAGONIST THERAPEUTICS INC in Q1 2019. The put-call ratio across all filers is - and the average weighting 0.2%.

Quarter-by-quarter ownership
BARCLAYS PLC ownership history of PROTAGONIST THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$2,950
-44.8%
176,837
-8.6%
0.00%
-33.3%
Q2 2023$5,344
-60.2%
193,439
-66.9%
0.00%
-50.0%
Q1 2023$13,427
+382.8%
583,737
+129.0%
0.01%
+500.0%
Q4 2022$2,781
-99.8%
254,887
+18.0%
0.00%
-50.0%
Q3 2022$1,820,000
+878.5%
215,994
+817.9%
0.00%
Q2 2022$186,000
-82.3%
23,531
-46.9%
0.00%
-100.0%
Q1 2022$1,050,000
-87.3%
44,302
-81.6%
0.00%
-50.0%
Q4 2021$8,248,000
+1157.3%
241,194
+551.9%
0.00%
Q3 2021$656,000
+97.0%
36,997
+399.6%
0.00%
Q2 2021$333,000
-66.1%
7,405
-80.4%
0.00%
-100.0%
Q1 2021$981,000
+358.4%
37,866
+257.0%
0.00%
Q4 2020$214,000
-24.6%
10,608
-27.0%
0.00%
Q3 2020$284,000
+27.9%
14,527
+15.4%
0.00%
Q2 2020$222,000
+428.6%
12,591
+113.7%
0.00%
Q1 2020$42,000
-67.7%
5,893
-68.1%
0.00%
Q4 2019$130,000
-25.3%
18,454
+27.3%
0.00%
Q3 2019$174,000
-42.4%
14,498
-41.9%
0.00%
Q2 2019$302,000
-62.8%
24,975
-61.3%
0.00%
-100.0%
Q1 2019$812,000
+75.8%
64,569
-5.9%
0.00%
Q4 2018$462,000
+181.7%
68,602
+179.7%
0.00%
Q2 2018$164,000
+60.8%
24,527
+106.5%
0.00%
Q1 2018$102,000
-40.4%
11,877
+44.6%
0.00%
Q4 2017$171,000
+4175.0%
8,216
+3703.7%
0.00%
Q3 2017$4,000
-20.0%
216
-53.4%
0.00%
Q2 2017$5,000
-75.0%
464
-71.6%
0.00%
Q1 2017$20,000
+300.0%
1,635
+650.0%
0.00%
Q4 2016$5,0002180.00%
Other shareholders
PROTAGONIST THERAPEUTICS INC shareholders Q1 2019
NameSharesValueWeighting ↓
JOHNSON & JOHNSON 2,449,183$43,400,0003.81%
BVF INC/IL 3,901,759$69,139,0002.70%
COMMODORE CAPITAL LP 498,079$8,826,0002.33%
Altium Capital Management LP 346,000$6,131,0001.61%
Twin Lakes Capital Management, LLC 139,287$2,468,0001.45%
Opaleye Management Inc. 330,222$5,852,0001.09%
EcoR1 Capital, LLC 1,443,800$25,584,0000.89%
OBERMEYER WOOD INVESTMENT COUNSEL, LLLP 776,689$13,763,0000.76%
JABODON PT CO 90,656$1,606,0000.66%
Artal Group S.A. 1,500,000$26,580,0000.60%
View complete list of PROTAGONIST THERAPEUTICS INC shareholders